89bio Inc logo

ETNB

89bio Inc

$5.34

Earnings Summary

Revenue
$0Mn
Net Profits
$-25.57Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

89bio Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, 89bio Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

89bio Inc’s net profit fell -72.95% since last year same period to $-25.57Mn in the Q1 2022. On a quarterly growth basis, 89bio Inc has generated 2.75% jump in its net profits since last 3-months.

Net Profit Margins:

89bio Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, 89bio Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the 89bio Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.07
EPS Estimate Current Year
-1.07

Highlights

EPS Estimate Current Quarter:

89bio Inc’s earning per share (EPS) estimates for the current quarter stand at -1.07 - a 17.05% jump from last quarter’s estimates.

EPS Estimate Current Year:

89bio Inc’s earning per share (EPS) estimates for the current year stand at -1.07.

Key Ratios

Key ratios of the 89bio Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.26
Return on Assets (ROA)
-0.37
Return on Equity (ROE)
-0.69
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

89bio Inc’s earning per share (EPS) fell -70.27% since last year same period to -1.26 in the Q1 2022. This indicates that the 89bio Inc has generated -70.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. 89bio Inc’s return on assets (ROA) stands at -0.37.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. 89bio Inc’s return on equity (ROE) stands at -0.69.

Dividend Per Share (DPS):

89bio Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-1.29
-1.26
2.33%

Company Information

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Organisation
89bio Inc
Employees
27
Industry
Health Technology